Eli Lilly and Company
RET KINASE INHIBITORS

Abstract:

Disclosed herein are compounds of formula I: ##STR00001## or a pharmaceutically acceptable salt thereof, where the variables are as defined herein. These compounds are useful in treating RET associated cancers. Formulations containing the compounds of formula I and methods of making the compounds of formula I are also disclosed.